Amryt Pharma plc, a commercial-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients suffering from serious and life-threatening rare diseases. The company offers Lomitapide for the treatment of homozygous familial hypercholesterolemia; and Metreleptin for the treatment of generalized and partial lipodystrophy. It also develops FILSUVEZ drug candidate, which is in Phase 3 EASE trial for the treatment of severe epidermolysis bullosa (EB), a rare and genetic skin disease; and AP103 that is in preclinical stage for the treatment of patients with recessive dystrophic EB, a subset of EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.

CEO

Dr. Joseph A. Wiley

Karyawan

182

Negara

Britania Raya

ISIN

US03217L1061

Pencatatan

STU

3N9A.STU

0 Comments

Bagikan pendapatmu

FAQ

Apa simbol saham Amryt Pharma?▼

Tergantung pada bursa, simbol saham dapat berbeda. Misalnya, di bursa Boerse Stuttgart, saham Amryt Pharma diperdagangkan dengan simbol 3N9A.STU.

Berapa jumlah karyawan Amryt Pharma?▼

Per Juli 26, 2026, perusahaan memiliki 182 karyawan.

Amryt Pharma berada di sektor apa?▼

Amryt Pharma beroperasi di sektor Kesehatan & Kebugaran.

Kapan Amryt Pharma menyelesaikan split saham?▼

Amryt Pharma belum melakukan split saham baru-baru ini.

Di mana kantor pusat Amryt Pharma?▼

Kantor pusat Amryt Pharma berlokasi di Dublin, Britania Raya.